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Abstract 
Particulate systems like 
micro/nanoparticles have been used as a 
physical approach to modify the 
pharmacokinetic and pharmacodynamic 
properties of various types of drug 
molecules increasing this way the drug 
bioavailability and avoiding the toxic level. 
The major advantages of the particulate 
systems include the protection of the drug 
entity in the systemic circulation, restriction 
access of the drug to the chosen sites and 
delivery of the drug at a controlled and 
sustained rate to the site of action. Various 
materials have been used in the formulation 
of micro/nanoparticles for drug delivery 
research to increase therapeutic benefit, 
while minimizing side effects. Each class of 
materials (metals, lipids, polymers) presents 
advantages which make them suitable for 
different classes of applications. This paper 
focuses mainly on polymer particulate 
systems due to their large applicability area 
given by the diversity of the polymers 
properties. We review various aspects of 
micro/nanoparticle formulation including 
preparation, release mechanisms, effect of 
their characteristics and their applications in 
the field of ophthalmology and 
neurosciences. Some of the most 
interesting applications of polymer 
micro/nanoparticulates in glaucoma, retinal 
disorders and optical nerve disorders, 
respectivelly in neurology and neurosurgery 
are presented. 
Keywords: controlled drug delivery, 
micro/nanoparticles, neuroscience, 
ophthalmology 
Introduction 
The word “micro/nanopharmaceutical” 
tends to be as magic as the message “Open 
Sesame!” for the diagnostic and treatment 
of diseases offering the opportunity to find 
new ways to attack the illness causes, 
respective complications and to improve the 
quality of patient life.  The goal of any drug 
delivery system is to provide a therapeutic 
amount of drug to the proper site in the 
body while achieving it rapidly and 
maintaining desired drug concentrations in 
the body circulation. Most drugs are 
delivered to patients using a systemic 
approach, the belief being that if you flood 
the body with enough active compounds, 
there will be a desired therapeutic effect on 
the body. The drug delivery systems are 
supposed to deliver the drug at a rate 
dictated by the needs of the body over a 
specified period of the treatment. The 
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idealized objective for the DDS points to 
two major aspects, namely spatial placement 
and temporal delivery of the drug. Spatial 
placement relates to targeting a drug to a 
specific organ or tissue. Temporal delivery 
refers to controlling the rate of delivery to 
the target tissues. The reduction or 
prevention of side effects can also be 
achieved by controlled release. 
Micro/nanoparticles provide a better 
penetration of the particles inside the body 
as their size allows delivery via intravenous 
injection or other routes. The 
micro/nanoscale size of these particulate 
systems also minimizes the irritant 
reactions at the injection site. [Thassu D. et 
al., 2009]. 
This paper focuses mainly on polymer 
particulate systems due to their large 
applicability area given by the diversity of 
the polymers properties. We review various 
aspects of micro/nanoparticle formulation 
including preparation, release mechanisms, 
effect of their characteristics and their 
applications in the field of ophthalmology 
and neurosciences. Some of the most 
interesting applications of polymer 
micro/nanoparticulates in glaucoma, retinal 
disorders and optical nerve disorders, 
respectivelly in neurology and neurosurgery 
are presented. 
Polymer micro/nanoparticles as controlled 
drug delivery system  
Micro/nanoparticulate drug-delivery 
systems are being explored for the purpose 
of solving the challenges of drug delivery. 
Coming in many shapes and sizes, micro 
and especially nanoparticles have the 
potential to eliminate or at least ameliorate 
many problems associated with drug 
distribution. As many drugs have a 
hydrophobic component, they often suffer 
from problems of precipitation in high 
concentration, and there are many examples 
of toxicity issues with excipients designed 
to prevent drug aggregation. To combat 
these issues, many micro/nanoparticulates 
provide both hydrophobic and hydrophilic 
environments, which facilitate drug 
solubility. Alternatively, many drugs suffer 
from rapid breakdown and/or clearance in 
vivo. Encapsulating the drugs in a 
protective environment, 
micro/nanoparticles increase their 
bioavailability, thereby allowing the 
clinicians to prescribe lower doses. 
The advantages of using nanoparticles as 
a drug delivery system include the 
following: 
1. Particle size and surface characteristics 
of nanoparticles can be easily manipulated 
to achieve both passive and active drug 
targeting after parenteral administration. 
2. They control and sustain release of the 
drug during the transportation and at the 
site of localization, altering organ 
distribution of the drug and subsequent 
clearance of the drug so as to achieve 
increase in drug therapeutic efficacy and 
reduction in side effects. 
3. Controlled release and particle 
degradation characteristics can be readily 
modulated by the choice of matrix 
constituents. Drug loading is relatively high 
and drugs can be incorporated into the 
systems without any chemical reaction; this 
is an important factor for preserving the 
drug activity. 
4. Site-specific targeting can be achieved 
by attaching targeting ligands to surface of 
particles, or use of magnetic guidance.  
5. The system can be used for various 
routes of administration including oral, 
nasal, parenteral, intra-ocular etc. 
In spite of these advantages, 
micro/nanoparticulate systems do have 
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limitations, for example their small size and 
large surface area can lead to particle 
aggregation, making physical handling of 
nanoparticles difficult in liquid and dry 
forms; also, the small particles size and large 
surface area readily result in limited drug 
loading and burst release.  
The micro/nanoparticles can be 
classified in the following main types,  
Particles can be prepared from a variety 
of materials such as proteins, 
polysaccharides and synthetic polymers. 
The selection of matrix materials is 
dependent on many factors including: (a) 
size of nanoparticles required; (b) the drug 
properties in terms of aqueous solubility 
and stability; (c) surface characteristics such 
as charge and permeability; (d) 
biodegradability, biocompatibility and 
toxicity; (e) The desired drug release 
profile; and (f) Antigenicity of the final 
product [Kreuter J., 1994].  
Depending on the desired properties, the 
micro/nanoparticles can be prepared by 
using either a chemical or a physical 
method, as presented in the Scheme 1. A 
variety of methods have been reported for 
producing micro/nanoparticles, chemical 
methods generally include: a) Preparation 
of the particles by polymerisation starting 
with a monomer and b) preparation of the 
particles directly from polymers, and 
physical methods assume only the use of 
polymers. 
 
 
Scheme 1 Micro/nanoparticles preparation methods 
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There are many mechanisms for drug release from micro/nanoparticulate systems, as 
described in the Scheme 2: 
 
Scheme 2 Schematic representation of the most important mechanisms of controlled drug release 
 
 
Figure 1 Different types of polymeric particles used as drug delivery systems  [Saltzman W. M., Drug Delivery 
Engineering Principles For Drug Therapy, 2001, Chapter 9.5. Particulate delivery systems, 
Oxford University Press] 
 
Several different classes of particulates 
with different release mechanisms are 
generally examined for use as drug delivery 
vehicles including microcapsules, 
microspheres, and 
nanospheres/nanocapsules (Figure 1) 
[Saltzman W. M., 2001]. Microcapsules 
consist of a polymer shell enclosing a drug-
loaded core. Microspheres are 
homogeneous particles in which the drug 
of interest is dispersed or dissolved within 
the solid polymer phase. Nanospheres are 
much smaller then microcapsules or 
microspheres. Nanospheres are usually 
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homogeneous particles, similar to 
microspheres, but they are frequently 
modified at the surface to increase their 
stability in the body or to provide targeting 
capability. 
The most common drug release 
mechanism for polymeric 
micro/nanoparticulate systems is 
represented by diffusion. There are two 
main types of polymer-drug systems where 
the release is mainly based on diffusion: 
reservoir system and monolith (matrix) 
system. The reservoir system is 
characterised by the fact that the bioactiv 
principle forming a core surrounded by a 
polymeric inert shell. In this case, the rate 
of diffusion of drug molecules through the 
membrane follows Fick’s Law and is thus 
dependent on the partition and diffusion 
coefficient of the drug in the membrane, 
the available surface area, the membrane 
thickness and the drug concentration 
gradient. If the drug concentration gradient 
remains constant, for example where solid 
drug particles are present and constant 
dissolution maintains the concentration of 
the drug in solution, the rate of drug release 
does not vary with time and zero order 
controlled release is attained. For the 
monolith system the bioactive principle is 
uniformly dispersed within a polymeric 
matrix which will control the release rate; 
this system implies the phsysical interaction 
between the drug and the polymer resulted 
from their co-processing. Regardless of a 
drug’s physical state in the polymeric 
matrix, such devices do not provide a zero-
order drug release kinetic. This is because 
as the drug molecules at the surface of the 
device are released, those in the centre of 
the device have to migrate longer distances 
to be released, which takes a longer time. 
This increased diffusion time results in a 
decrease in the release rate from the device 
with time. Generally the rate of release is 
found to decrease in proportion to the 
square root of time (“M t1/2” kinetics) 
[Hillery A. M., 2001]. 
In erosion-controlled drug release 
systems, drug release is controlled by 
adjusting the dissolution / erosion rate of 
the polymer. The erosion of polymeric 
materials is the most important factor of 
this mechanism; that’s why the polymers 
used must be water soluble and/or 
degradable in water. The choice of a 
specific polymer for a particular controlled 
release dosage form depends on various 
factors such as the dissolution mechanism, 
delivery period, delivery route, the drug etc. 
In the case of the systems controlled by 
osmosis it is important to mention that the 
Osmosis is defined as the movement of 
water through a semi-permeable membrane 
into a solution. This movement of water 
will determine an increase in pressure in 
the solution and the excess pressure is 
known as the osmotic pressure which can 
be used to pump out the drug at a constant 
rate from the delivery system so that drug 
release is zero order.  
Bio-responsive controlled drug delivery 
systems should adjust the drug release in 
respect to certain changes in the external 
environment like pH or ionic strength, 
temperature.  
Nanoparticles are solid particles ranging 
in size from 10 nm to 1000 nm (1 μm). 
They consist of macromolecular materials 
in which the active principle (drug or 
biologically active material) is dissolved, 
entrapped, or encapsulated, and/or to which 
the active material is adsorbed or attached. 
Microparticles are similar particles in the 
size range of 1 μm to 1000 μm (1 mm) 
[Kreuter J., 1996].  
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Figure 2 Types of carriers for particulate drug delivery: A polymeric nanoparticles: polymeric nanoparticles in 
which drugs are conjugated to or encapsulated in polymers. B polymeric micelles: amphiphilic block 
copolymers that form core/shell structures in aqueous solution. C dendrimers: synthetic polymeric 
macromolecule of nanometer dimensions, which is composed of multiple highly branched monomers that 
emerge radially from the central core. D liposomes: self-assembling structures composed of lipid bilayers in 
which an aqueous volume is entirely enclosed by a membranous lipid bilayer. E viral-based nanoparticles: in 
general structure are the protein cages, which are multivalent, self-assembles structures. F carbon nanotubes: 
carbon cylinders composed of benzene rings. [Kwangjae C., Wang X., Nie S., Chen Z., Dong M. Shin, 
Therapeutic Nanoparticles for Drug Delivery in Cancer, 2008, Clin Cancer Res., 14: 1310] 
 
As it can be observed in the figure 2 
there are different types of polymer 
particles especially designed in order to 
cover all needs in terms of application and 
administration path.[ Kwangjae C. et al, 
2008].  
I. Application of micro/nanopharmaceutics 
in ophthalmology  
Despite numerous scientific efforts, 
efficient ocular drug delivery remains a 
great challenge for scientists, currently most 
of the ocular diseases are treated by topical 
drug application in the form of solutions, 
suspensions and ointment. These 
conventional dosage forms suffer from the 
problems of poor ocular bioavailability, 
because of various anatomical and 
pathophysiological barriers prevailing in the 
eye. 
One of the most important problem of 
the eye as a target organ, from therapeutic 
point of view is the presence of several 
barriers that impede direct and systemic 
drug access to the specific site of action. 
Superficial barriers include the ocular 
surface epithelium and the tear film, and 
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internal barriers include the blood-aqueous 
and blood-retina barriers. Topical 
application of the drugs is the preferred 
route at ocular level, even when the target 
tissues are at the back part of the eye where 
intraocular injections are currently the most 
common route of administration. The 
advantages of using micro/nanoparticles 
include improved topical passage of large, 
poorly water-soluble molecules such as 
glucocorticoid drugs or cyclosporine for 
immune-related, vision-threatening 
diseases [Diebold Y., 2010]. 
Interesting examples concerning the 
applications of  polymer 
micro/nanotechnology are presented in 
correlation with the following ocular 
disorders: 
A. Glaucoma 
B. Retinal disorders 
C. Optical nerve disorders 
A. Applications of the micro/nanoparticles in 
glaucoma 
Glaucoma is defined as an optic 
neuropathy, which is diagnosed clinically 
from its characteristic disk appearance and 
typical changes in the visual field and which 
can be caused by various risk factors 
including raised intraocular pressure. The 
goal of glaucoma treatment is avoidance of 
further progression of the disease by 
lowering the intraocular pressure. Various 
types of drugs are currently in use in 
different formulations. One of the major 
disadvantages of all locally applied 
antiglaucoma drops is intolerance reactions 
and local cytotoxic effects. The main classes 
of drugs used in therapy of glaucoma are: 
sympathomimetics, sympatholytics, 
carbonic anhydrase inhibitors, 
parasympathomimetics (cholinergics), 
prostaglandin derivatives, osmotic agents. 
Casalengua et colab. have developed a 
microparticulate system based on 
poly(lactic-co-glycolic acid) (PLGA) in 
which they have encapsulated GDNF (glial 
cell line-derived 31 neurotrophic factor) 
used as protector in glaucoma treatment, in 
combination with vitamin E and intravitreal 
administered in rats which were artificially 
glaucoma induced [Checa-Casalengua P. Et 
al., 2011]. The neurotrophic factor 
(GDNF) in combination with vitamin E 
released from the microspheres was 
demonstrated to be effective for at least 
eleven weeks after a single intravitreal 
injection; the efficacy of the treatment was 
measured in terms of retinal glial cells loss 
(figure 3). This approach should be 
considered as a future treatment of retinal 
degenerative diseases, as intravitreal PLGA 
administration is safe and effective, with no 
obvious side effects on the retinal integrity. 
Another interesting study is provided by  
Dos Santos et al. and is related to the 
wound healing of conjunctiva after 
glaucoma filtration surgery [Gomes dos 
Santos A. L. Et al., 2006]. For this, they 
have prepared PLGA microspheres in 
which transforming growth factor-β (TGF-
β) or 2′-O-methoxyethyl modified 
phosphorothioate antisense oligonucleotide 
(AsPS-ODN) – as bioactive principle were 
entrapped and subconjunctival injected. 
The authors designed PLGA microspheres 
(PLGA-MS) containing PS-ODN either 
naked (MS-PS-ODN) or complexed (MS-
PS-ODN-PEI) and the most appropriate 
formulation was then tested in an 
experimental model of filtering surgery in 
rabbits being the first time that a system 
combining sustained release and enhanced 
intracellular penetration of antisense ODN 
was successfully assessed in an in vivo 
model (figure 4). 
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Figure 3 I - SEM images of GDNF-loaded microspheres; II - Confocal microscopy images of nile red labelled 
PLGA microspheres. (A) MS elaborated with PLGA and nile red. The absence of dye might be related with a 
inner porous structure. (B) MS elaborated with PLGA, vit E and BSA-FITC. Protein was mainly located near to 
MS surfaces. (C) MS elaborated with PLGA, Vit E and TRITC-DHPE as lipid dye. The oily lipids (vit E and 
dye) were distributed in all the MS, but was mainly located close to the MS surface. (D) MS elaborated with 
PLGA, Vit E, TRITC-DHPE, and BSA-FITC. A heterogeneous distribution was observed with higher 
quantities of protein and oily additive close to the MS surface [Checa-Casalengua P., Jiang C., Bravo-Osuna I., 
Budd A. Tucker ,Irene T. Molina-Martínez, Michael J. Young, Rocío Herrero-Vanrell “Retinal ganglion cells 
survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel 
microencapsulation procedure”, 2011, Control. Release,  doi:10.1016/j.jconrel.2011.06.023]. 
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Figure 4 Fluorescent photographs of cryosections of the rabbit conjunctiva 1 day after subconjunctival injection. 
A Microspheres made of PLGA labelled with Nile red are seen in red and B complexes made with FITC ODNs 
and PEI are seen in green. C Combination with DAPI nuclei staining (blue) shows the microspheres in the 
tissue (arrows). D Higher magnification shows one microsphere with pores and complexes containing FITC 
labelled ODN next to a nucleus. Scale bar=20μm [Gomes dos Santos A. L., Bochot A., Doyle A., Tsapis N., 
Siepmann J., Siepmann F., Schmaler J., Besnard M., Behar-Cohen F., Fattal E., “Sustained release of nanosized 
complexes of polyethylenimine and anti-TGF-β2 oligonucleotide improves the outcome of glaucoma surgery”, 
2006, Journal of Controlled Release, 112-3-369-381]. 
 
Nanosized complexes used were shown 
first to enhance the intracellular penetration 
of antiTGFβ2 and also to down regulate 
TGFβ2 in Rat Retinal Müller Glial cells as 
shown by RTPCR and Elisa. Nanosized 
complexes having an adequate 
encapsulation efficiency and release profiles 
allowed to improve the outcome of 
glaucoma filtration surgery. 
B. Applications of the micro/nanoparticles in 
retinal disorders 
Retinal drug delivery is one of the most 
challenging area in the field of ophthalmic 
drug delivery. An ideal drug delivery system 
for the retina and vitreous humor has not 
yet been found, despite extensive research. 
Drug delivery to retinal tissue and vitreous 
via systemic administration is constrained 
due to the presence of a blood-retinal 
barrier (BRB) which restrains the 
permeation of substances from blood to the 
retina. Although intravitreal administration 
overcomes this barrier, it is associated with 
several other problems. In recent years, 
transporter targeted drug delivery has 
become a clinically significant drug delivery 
approach for enhancing the bioavailabilities 
of drug molecules with poor membrane 
permeability characteristics. Various 
nutrient transporters, which include 
peptide, amino acid, folate, monocarboxylic 
acid transporters and so on, have been 
reported to be expressed on the retina and 
BRB. Prodrug derivatisation of drug 
molecules which target these transporters 
could result in enhanced ocular 
bioavailability [Duvvuri S. et al, 2003]. 
Kim’s research group have studied the 
biodistribution of intravitreal human serum 
albumin nanoparticle (HSA-NP) and the 
mechanism for transretinal penetration of 
intravitreal nanoparticles into the subretinal 
space; the reason for using this kind of 
nanoparticles  is that they showed excellent 
intraocular tolerance [Kim H. et al., 2009]. 
Nanoparticles having under 100 nm were 
prepared using dessolvatation-crosslinking 
technique and part of them were then 
cathionized with ethylenediamine   by 
covalent coupling at carboxyl groups.  
 
 
Figure 5 The vitreal distribution of Alexa 555 
(fluorescent dye) conjugated A cationic and B 
anionic HSA-NP 5 h post intravitreal administration 
[Kim H., Robinson S. B., Csaky K. G., “Investigating 
the Movement of Intravitreal Human Serum 
Albumin Nanoparticles in the Vitreous and Retina”, 
2009, Pharmaceutical Research 26 (2): 329-337] 
 
Figure 5 shows the vitreal distribution of 
cationic HSA-NP (A) and anionic HSA-
NP (B) 5 h post intravitreal administration. 
The cationic HSA-NPs were filtered and 
could not penetrate the vitreous, but most 
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of intravitreal anionic HSA-NPs penetrated 
the vitreous and were located within the 
retina at 5 h. Anionic HSA-NPs penetrated 
the vitreal barrier more easily than cationic 
HSA-NPs, the author’s explanation being 
the electrostatic attraction between cationic 
HSA-NPs and the negatively charged 
vitreal glycosaminoglycan. Also, the authors 
have shown the transretinal penetration of 
HSA-NP into the RPE in normal retina 
and laser coagulated retina 5 h post 
intravitreal injection. Another interesting 
observation is that trans-retinal penetration 
of HSA-NP occurs through a specific 
route. The anionic HSA-NP were proved 
to be a promising drug delivery carrier for 
the treatment of age-related macular 
degeneration as HSA-NPs were observed to 
reach the choroid through the disruption 
site of the RPE and Bruch’s membrane. 
Rafat et al. have evaluated polyethylene 
glycol-polylactic acid (PEG–PLA) 
microparticles for encapsulation and 
delivery of a Transactivator of 
transcription-enhanced green fluorescent 
protein fusion (Tat-EGFP) to retinal cells; 
microparticles were also analysed in vivo by 
sub-retinal injection into rat eyes. The 
microparticles were proved to be 
appropriate for targeted delivery to cells at 
the back of the retina (i.e. photoreceptor 
cells), which could prove effective in the 
treatment of blinding diseases caused by 
photoreceptor cell loss. They also can 
effectively deliver proteins to the outer 
segment of the retina, without any apparent 
cytotoxic effects. PEG–PLA microparticles 
show great potential for sustained ocular 
drug delivery because of their high stability 
in vitro and in vivo, and their release profile 
(figure 6) [Rafat M. et al., 2010]. 
Another example was raised from the 
following need: the dysfunction of RPE 
cells can cause disruption in the neural 
retinal homeostasis, the RPE being this way 
an important target tissue for ocular therapy 
due to the fact that continuous phagocytosis 
of the photoreceptor outer segments is an 
important function of retinal pigment 
epithelium (RPE) in maintaining the health 
of the neural retina. Due to the poor 
accessibility of drugs to the RPE by 
conventional drug delivery systems, 
Tuovinen and her research group have 
studied starch acetate microparticles for 
delivery of drugs to the retina [L. Tuovinen  
et al, 2004]. For this, the cellular uptake of 
starch acetate microparticles and 
degradation of starch acetate by cultured 
human RPE-cell line (D407) was 
examined. 
The results after the incubation of 
cultured RPE cells with blank or calcein-
containing starch acetate microparticles 
reveal that they did not markedly affect the 
viability of the cells: after 3-or 24-h 
incubation, the viability was at least 93%, 
this is probably due to the fact that starch-
based polymers have been shown to be 
biocompatible and acetyl starch is actually 
used as a human plasma volume expander 
(figure 7). 
C. Applications of the micro/nanoparticles in 
optic nerve disorders 
Very recent work made by Rong et al. 
explored a sustained neuroprotective 
erythropoietin (EPO) loaded composite 
microspheres system on injured retinal 
ganglion cells (RGC) [Rong X. et al., 2011]. 
EPO, naturally occured in the body, is 
well known for its neuroprotective and/or 
but also for the ability to cross the blood-
brain barrier and blood-retina barrier when 
systemically applied. It was developed a 
new method for encapsulation of EPO: the 
EPO was first loaded into dextran 
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microparticles (figure 8) to keep its 
bioactivity and the final microspheres were 
formed by encapsulating the primary 
dextran microparticles into poly (DL-
lactide-co-glycolide)/Poly (DL-lactide) 
(PLGA/PLA). 
 
 
Figure 6 A - Scanning electron microscopy (SEM) images of PEG–PLA microparticle formulations; B - 
Fluorescence microscopy - cellular uptake of Tat-EGFP released from PEG–PLA microparticles in mouse 
photoreceptor-derived 661 W cells after 48 hours [Rafat M., Cleroux C. A., Fong W. G., Baker A. N., Leonard 
B. C., M. D. O’Connor, C. Tsilfidis, “PEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to 
retinal cells”, 2010, Biomaterials 31: 3414–3421] 
 
 
Figure 7. Confocal microscopy, (A) fluorescence and (B) light microscopic images of living RPE-cell culture 
after 24-h incubation with starch acetate microparticles. Microparticles in the cell are shown by an arrow and 
outside of cell by arrowheads. Bar indicates 6 μm; C - Scanning electron microphotograph (2000x) of starch 
acetate microparticles [Tuovinen L., E. Ruhanen, T. Kinnarinen, S. Ronkko, J. Pelkonen, A. Urtti, S. Peltonen, 
K. Jarvinen, “Starch acetate microparticles for drug delivery into retinal pigment epithelium—in vitro study”, 
2004, Journal of Controlled Release 98: 407– 413] 
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Figure 8 Scanning electron microscopic images of 
EPO-loaded PLGA/PLA microspheres [Rong X., 
Moa X., Ren T., Yang S., Yuan W., Dong J., Wang Y., 
Wang X. „Neuroprotective effect of erythropoietin-
loaded composite microspheres on retinal ganglion 
cells in rats”, 2011, European Journal of 
Pharmaceutical Sciences, 43: 334–342]. 
 
The authors have investigated theirs 
therapeutic efficacy on RGC in an optic 
nerve crush model through single 
intraperitone injection and compared it 
with the multiple injections of EPO 
solution. EPO-loaded PLGA/PLA 
microspheres showed a stable sustained 
release profile and significantly promoted 
RGC survival in optic nerve crush rats for a 
prolonged period when delivered through 
an intraperitone injection, showing that this 
delivery system can be used as an effective 
drug delivery system for EPO to prevent 
cell death from neurodegenerative CNS 
diseases such as glaucoma in ocular, stroke, 
and Alzheimer’s. 
II.  Application of micro/nanopharmaceutics 
in neurology and neurosurgery 
The application of nanotechnology in 
cell biology and physiology enables targeted 
interactions at a fundamental molecular 
level. In neuroscience, this entails specific 
interactions with neurons and glial cells. 
Examples of current research include 
technologies that are designed to better 
interact with neural cells, advanced 
molecular imaging technologies, materials 
and hybrid molecules used in neural 
regeneration, neuroprotection, and targeted 
delivery of drugs and small molecules 
across the blood–brain barrier.  
Applications of nanotechnology in basic 
and clinical neuroscience are only in the 
early stages of development, partly because 
of the complexities associated with 
interacting with neural cells and the 
mammalian nervous system. Despite this, 
an impressive body of research is emerging 
that hints at the potential contributions 
these technologies could make to 
neuroscience research. Gabriel A. Silva in 
the following schema has organized the 
main classes of nano/microtechnology 
applications in the field of clinical 
neuroscience [Silva G. A., 2006]. 
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Scheme 3 Applications of nanotechnology in clinical neuroscience a. neuroprotection - limiting the effects of 
free radicals produced following trauma (for example, those produced by CNS secondary injury mechanisms); 
b. nanoengineered scaffold materials that mimic the extracellular matrix and provide a physical and/or bioactive 
environment for neural regeneration. c. Nanoparticles as drug delivery systems for the transport of drugs and 
small molecules across the blood–brain barrier [Silva G. A. “Neuroscience nanotechnology: progress, 
opportunities and challenges”, 2006, Nature Reviews , Neuroscience, 7] 
 
In the following paragraphs examples 
representing new frontiers of 
micro/nanotechnology in clinical 
neuroscience will be presented.  
Kim and his research group have 
developed a nanoparticle system based on 
poly(lactic-co-glycolic acid) (PLGA) for 
methylprednisolone (MP) local delivery at 
spinal cord injury level;  
methylprednisolone is generally used to 
reduce neurological deficits after acute 
spinal cord injury [Kim Y. Et al., 2009]. 
The conclusions of the study presented 
offer the potential advantages of MP-NP 
local delivery over conventional systemic 
delivery are as follows 
1) Better therapeutic effect: The 
sustained and local delivery of MP 
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demonstrates significantly improved 
therapeutic effects on the injured spinal 
cord as compared to systemic MP delivery 
2) More efficient, targeted delivery to 
the injury site (they have used a 
significantly lower dose of nanoparticle-
encapsulated MP avoiding the side effects 
associated with high doses) 
3) The possibility of adjusting the dose 
and the delivery rate 
Wang et al. have performed GDNF 
(Glial cell line derived neurotrophic factor),  
which induces neuronal survival and tissue 
repair after spinal cord injury, encapsulated 
in PLGA (PLGA-GDNF) nanoparticles and 
administered by intraspinal injection 
proximal to the lesion of the injured spinal 
cord center [Y.C. Wang et al., 2008]. The 
therapeutic effect of PLGA-GDNF on the 
injured spinal cord was evaluated by 
examining the preservation of 
neurofilament (NF)-stained neuronal fibers 
and functional recovery using the Basso 
Beattie Bresnahan (BBB) locomotor rating 
scale. They have also investigated whether 
local administration of PLGA-GDNF 
affected glial activity in the injured spinal 
cord by immunofluorescence against glial 
fibrillary acidic protein (GFAP) for 
reactivated astrocytes, and ionized calcium 
binding adapter molecule (Iba1), a marker 
for activated microglia. The main 
conclusion of this study was that GDNF 
loaded in PLGA could be continually 
released and remains bioactive in the 
injured spinal cord, which in turn induces 
an increase in neuronal survival and 
improves better hindlimb locomotion 
function in spinal cord injured rats.  
Another interesting example is given by 
Etame et al. in their study concerning the 
influence of the polyethylene glycol (PEG) 
chain used for covering the Au 
nanoparticles on the permeability of brain 
microvasculature, being already well known 
that Au nanoparticles may have potential 
relevance for brain tumor passive targeting 
[Etame A. B. et al., 2011],. The authors 
have designed an in-vitro model to mimic 
the transport-permissive brain 
microvasculature, demonstrating size-
dependent permeation properties with 
respect to core particle size and PEG chain 
length. In general short PEG chain length 
(molecular weight 1000–2000) in 
combination with smallest core size led to 
optimum permeation in our model system. 
The invasive superficial and ventricular 
application of chemical or the application of 
drugs to brain parenchyma represent the 
main task for delivery at the brain level; the 
classical administration of drugs generally 
affect the patient compliance, involves more 
laborious and requiring specialized skill in 
order to not produce permanent damage to 
the brain. In view of these considerations, 
novel drug delivery systems such as the 
nanoparticles are being explored for their 
suitability for targeted brain delivery.  
Abattastini et al. developed 
indomethacin-loaded nanocapsules using 
indomethacin, poly(e-caprolactone), 
capric/caprylic triglyceride and sorbitan 
monostearate [Battastini A.M.O. et col, 
2009]. Although indomethacin is not an 
agent used in the treatment of brain 
tumors, the study in rats with implanted C6 
glioma demonstrated the effectiveness of 
sub-therapeutic (1 mg/(kg day)) dose of 
indomethacin-loaded nanocapsules to avert 
mortality and toxicity, while improving the 
body weight of treated animals, compared 
to the control group. 
Alzheimer’s is a progressive and fatal 
brain disease and the most common form 
of dementia. In the last years, it was found 
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that nanoparticles could serve as efficient 
carriers of imaging agents for Alzheimer’s 
disease. A recent study have evaluate the 
release of radiolabeled clioquinol from 
butyl cyanoacrylate nanoparticles and their 
efficiency in imaging plaques during tests 
on animal models with Alzheimer’s disease 
[Kulkarni P., 2007]. Autoradiography 
images showed localized uptake in brains of 
experimental animals, and was more 
pronounced in animals injected with 
clioquinol- nanoparticles compared to 
clioquinol itself. 
The most malignant type of astrocytoma, 
glioblastoma, is the most common tumor of 
the central nervous system. One of the 
most promising therapeutic solutions for 
the treatment of human glioblastoma is the 
polymer nanoparticles–doxorubicin 
formulation. There are a lot of studies 
[Jătariu A. N. et al., 2010]. concerning this 
type of formulation, using different 
polymers and preparations methods and 
offering new opportunities for noninvasive 
chemotherapy of brain tumors. 
Conclusions 
Micro and nanoparticles represent 
promising drug carriers for ophthalmic and 
neurologic applications. The drug release 
properties depends on the physicochemical 
properties of the drugs as well as of the 
nano- and microparticle material and also 
on the manufacturing process for the 
particles. Generally, after optimal drug 
loading within the particles, the ocular 
bioavailability of many drugs is significantly 
enhanced in comparison to classical 
formulations. Also, in the case of 
neuroscience many drug delivery systems, 
especially in particulate form were found to 
be suitable for application in healing after 
complicated surgery or passing the blood – 
brain barrier. The increasing ability to 
deliver the biologic active principles in a 
safe and effective way offer new 
opportunities to treat many of the 
ophthalmologic and neurologic diseases. 
The technologies required to deliver agents 
specifically and effectively to the target 
organs are rapidly evolving, the next years 
promise a real progress in therapy for many 
poorly treated or untreatable diseases. 
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